Immatics N.V. (IMTX) vs Inhibrx Biosciences (INBX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Inhibrx Biosciences (INBX) has outperformed Immatics N.V. (IMTX) over the past year, gaining 178.7% versus a loss of 20.8%. Inhibrx Biosciences is the larger company by market cap ($1.35 billion vs $1.10 billion), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IMTX | INBX |
|---|---|---|
| Share price | $7.26 | $91.44 |
| Market cap | $1.10B | $1.35B |
| 1-day change | -2.60% | -2.06% |
| YTD return | -29.05% | +18.18% |
| 1-year return | -20.83% | +178.69% |
| 5-year return | -46.21% | — |
| EPS (TTM) | $-1.87 | $-8.88 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $12.41 | $155.29 |
| 52-week low | $7.22 | $28.16 |
| Distance from 52-week high | -41.53% | -41.12% |
| Analyst consensus | none | none |
| Avg. price target upside | +142.97% | +191.63% |
| Average volume | 595.07K | 291.93K |
| Shares outstanding | 152.23M | 14.72M |
| Employees | 704 | 109 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- INBX has outperformed IMTX by 199.5 percentage points over the past year.
About Immatics N.V.
IMTX stock →Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 704 employees
About Inhibrx Biosciences
INBX stock →Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates include INBRX-109, which is in phase 1, a tetravalent therapeutic candidate targeting death-receptor 5 to treat unresectable or metastatic conventional chondrosarcoma; and INBRX-106, a hexavalent sdAb-based therapeutic candidate targeting OX4 for the treatment of metastatic solid tumor, non-small cell lung cancer, melanoma, head non-small cell lung cancer cell carcinoma, gastric or gastroesophageal junction adenocarcinoma, renal cell carcinoma, and urothelial cell carcinoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 109 employees
IMTX vs INBX FAQ
Which is bigger, Immatics N.V. or Inhibrx Biosciences?
Inhibrx Biosciences (INBX) is larger, with a market capitalization of $1.35B compared with $1.10B for Immatics N.V. (IMTX).
Which stock has performed better over the past year, IMTX or INBX?
INBX returned +178.69% over the past 12 months, compared with -20.83% for IMTX (price return, excluding dividends). Past performance does not predict future results.
Are Immatics N.V. and Inhibrx Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.